1

November 2015

CONFIDENTIAL

Public, Private, and ResearchCURING TODAY…INNOVATING FOR TOMORROW

2

A Comprehensive Approach

Cord Blood Stem Cell Banking

Private Adult Stem Cell Banking

Public Banking

Cellular Therapy

Biological Safety Deposit Box

CONFIDENTIAL

FDA

Changing the Model

Cord Blood Banking

3

Pillars of the Business3 Divisions

FDA drug license

Cord Blood Banking Adult Banking Public Banking

20 years but still “new” to consumers 1st in class

Multibillion dollar market CU partnerships and collaborations

Strong recurring revenues

Possible exclusivity

National programHigh profit potential

CONFIDENTIAL

4

High PotentialPublic, Private, and Research

Private Banking Adult Banking

• Twenty years of use and technical ability

• Multi-billion dollar consumer business in place and maturing

• Dominated by marketing companies

• Strong recurring revenues

• Opportunity to take share

• New product

• Market introduction

• High end target market

• Collections through blood centers nationwide

Public

• FDA drug license

• Regenerative medicine research

• Leverage university assets

CONFIDENTIAL

5

• 32 acre medical campus • 6.4 million square feet • 7,000+ faculty members

• 21,000+ employees• Serving over 500,000 patients annually• Established in 1883

University of ColoradoThe Medical Campus

CONFIDENTIAL

6

Part of an Integrated Medical Center

The University of Colorado School of Medicine

Bioengineering and Applied Science

Bioscience Park

University of Colorado Hospital

Gates Center for Regenerative Medicine

Children’s Hospital Colorado

At the University of Colorado

CONFIDENTIAL

Anschutz Medical Campus

7

• Administered by transplant physicians and histocompatibility scientists committed to improving patient transplant outcomes

• Collecting and banking umbilical cord blood since 1996; accredited by the AABB• Class 10,000 cGMP stem cell processing facility• HRSA Contractor for National Cord Blood Inventory (NCBI) since 2006• Cord blood units are available through the NMDP• Confirmatory HLA typing • More than 750 units released for patient transplants• Units shipped to more than 120 transplant programs in Argentina, Australia, Belgium,

Brazil, Canada, China, France, Italy, Mexico, New Zealand, Spain, United Kingdom, Uruguay, and the United States

• 50% of units are from minority donors • FDA License No. 1855, received on May 24th, 2012

Public Cord Blood Banking

Processing Cord Blood Units under License for 3 Years

Processing Donated Cord Blood Units for 18 Years

Inventory of 10,000+ Cord Blood Units

FDA License No. 1855, Received May 24th, 2012

CONFIDENTIAL

8

ClinImmune LabsAt the University Of Colorado

CONFIDENTIAL

Dr. Brian FreedExecutive Director and Professor at the University of Colorado’s School of Medicine

Sharon Miller, CHS MTDirector of Regulatory Affairs

Regulatory

MichaelAubrey, MSChief Operating Officer

Operations

TateHermansonDirector of Business Services

Administration

Dr. Ralph QuinonesDirector of Blood and Marrow Processing Laboratory

Co-Medical Director

Dr. JonathanGutmanClinical Director of Allogeneic Transplantation

Co-Medical Director

Executive Director

9

ClinImmune is Comprised of Six Laboratories

These laboratories provide services to kidney, heart, lung, pancreas, and hematopoietic stem cell transplant programs including: University of Colorado Hospital, Colorado Children’s Hospital, Presbyterian/St. Luke’s (Denver, Colorado), Northside Hospital (Atlanta, Georgia), and St. Francis Hospital (Charleston, South Carolina).

Providing Services to Hospitals Nationwide

HistocompatibilityClinical ImmunologyFlow Cytometry

CariCordHuman Stem Cell ProcessingPublic Cord Blood Bank is FDA Licensed

18 years

Expertise and Experience

CONFIDENTIAL

10

New Laboratory Opened 2015

CONFIDENTIAL

Largest Medical School Construction Project in the USAt the University of Colorado

In 2013, the University of Colorado Board of Regents approved a new Bioscience 2 facility which will contain our state of the art Class 10,000 cGMP lab. The University celebrated with a Grand Opening Ceremony on 11/18 2015. The District’s adjacency to the Anschutz Medical Campus and its formal affiliation with the University of Colorado provides priority access and support for research and product development.

11

• CariCord is a stem cell services company providing best in class cord blood and tissue preservation, focused on improving the health, wellness and quality of life of families who choose to save their baby’s stem cells at birth.

• A component of ClinImmune Labs at the University of Colorado, CariCord combines the latest scientific research with ongoing feedback from both transplant physicians and the research community to maintain its cutting edge quality standards within the newborn stem cell storage market.

• 2014, CariCord launched our initial sales efforts to both the OBGYNs, utilizing an experienced management team and concurrently direct to consumers, via advertising and a call center with sales agents. We have seen rapid acceptance of our offering and core messages: Stability, Quality and Experience.

• 2015, we have built a scalable model and are seeking investment partners to facilitate rapid growth, as we fuel our market launch and upwards growth trajectory.

About CariCordA Unique Model with a Strong Message

CONFIDENTIAL

12

Experienced Leadership TeamOver 50 Combined Years of Cord Blood Industry Knowledge

Calvin ColePresident & CEO

President

Brian McEnroeSr. VP Sales & Marketing

Sales and Marketing

Ranelle EricksonVP of Marketing

Marketing

John GabrielSr. VP Operations

Operations

Dub SittonVP of Sales

Sales

Jim ToddChief Financial Officer

Finance

Global Medical Director

Ratan Bhardwaj MD, PhD, Pediatric Neurosurgery

Medical Director

Donald Vliegenthart MD, Board Certified Orthopedic Surgeon

Scientific

Harry KloorPhD, PhD Chief Scientific Officer

CONFIDENTIAL

13Alaska Hawaii

Growing Footprint States We Have Conducted Business In (Light Blue)

14

We have been processing cord blood units under federal contract since 2006. We were among the first to elevate our cord blood banking practices to FDA BLA licensure. I’m pleased to announce we are the first to leverage our lab’s best practices to serve private consumers, while sustaining our efforts to build the National Cord Blood Inventory with life-saving transplant ready units. We believe our partnership in CariCord demonstrates a sustainable pathway that is responsive to current and future private and federal sector demands.

“

”Brian Freed

Executive Director of ClinImmune Labs and Professor at the University

of Colorado’s School of Medicine

Quality BankingHistory of Expertise Now Available to Families

CONFIDENTIAL

15

Cord Blood BankingFamilies can choose to preserve their baby’s cord blood at the time of birth, utilizing our temperature controlled collection kit. Cord blood is currently used to treat over 80 diseases with many more in research.

Cord Tissue BankingFamilies can also choose to save their baby's cord tissue at delivery, using the CariCord collection kit cup, always available inside our kit. Cord tissue stem cells show promising therapeutic potential in pre-clinical research for diseases such as stroke, diabetes, Parkinson’s disease, ligament repair in sports injuries, liver and lung repair and wound healing.

Product PipelineAdult Stem Cell Banking is currently under development and details of the project are confidential at this time.The project will have broad appeal and will save qualitystem cells, for those who enroll. Announcements regardingthe details are dependent on harvesting, processing and storage and will be coming in the next 90 -180 days,if not sooner.

Our ProductsCurrent Offerings

CONFIDENTIAL

16

CariCord’s goal is to become the # 1 cord blood and tissue company recommended by health care providers, to all patients. We also plan to develop a comprehensive line of stem cell storage options for adult stem cells from alternative sources. Key elements of the CariCord’s strategy to achieve this goal are as follows:

Our Growth StrategyPositioned for Success

Building the National Cord Blood SupplyWe plan to combine the private and public cord blood banks and increase the number of donation hospitals, with a goal of creating large volume, FDA licensed cord blood units, to provide to families and healthcare professionals seeking lifesaving units for transplant.

Focus on ResearchWe plan to expand our efforts on research, clinical trials, and commercialization of stem cell related products. Therapies that improve the quality of life, recovery, and outcomes for diseases treated with stem cells, will increase the demand for stem cell storage and therapeutic treatment options for patients.

Exclusive Current Market Focus Initially, we plan to focus exclusively on cord blood and tissue banking, focusing on superior quality and long term stability, demonstrating to physicians that they can be confident recommending CariCord to patients and families.

CONFIDENTIAL

17

Class 10,000 clean rooms

Laboratory capacity

Oversight and management

CLINICAL TRIALS

Clinical Trial Center – Research and DevelopmentAdvancing Stem Cell Science

CONFIDENTIAL

COLLABORATION

PATH TO NEW TREATMENTS

Dedicated partner

Researchers

Academic medical center

Commercialization

Testing for safety and efficacy

Creation of novel cellular products

18

Crag T. Jordan, MDDr. Jordan serves as the Chief of the Hematology Division and directs a research program focused on the development of novel therapies for the treatment of leukemia.

Brian M. Freed, PhD, DABHIDr. Freed is Executive Director of ClinImmune Labs and a Professor of Medicine and Immunology. ClinImmune Labs consists of the Histocompatibility Lab, the Stem Cell Lab, the University of Colorado Cord Blood Bank, the Flow Cytometry Lab and CariCord. His research focuses on the role of individual HLA amino acid residues in antigen presentation with the goal of providing HLA-specific immunotherapy.

Johnathan Gutman, MDDr. Gutman directs the Allogeneic Bone Barrow Transplant (BMT) program and is a leading expert in the use of umbilical cord blood derived stem cells for BMT. He oversees a broad range of clinical programs and trials.

Clay Smith, MDDr. Smith is the Associate Chief of Hematology and the Clinical Director for the Blood Cancer Program. He is a highly experienced laboratory researcher and directs a program focused on the development of new therapeutic regimens in the treatment of hematologic malignancies.

Jill Slansky, PhDUsing an animal model for colon cancer, Dr. Slansky is determining what substitutions in tumor antigen peptides can be used to improve antitumor immunity. These so-called mimotope peptides (mimics of epitopes) activate T cells that respond to the tumor more effectively than the natural tumor antigen.

Ross Kedl, PhDDr. Kedl is interested in this curious boundary between the innate and adaptive immune systems and seeks to elucidate signals and pathways emanating from the various families of innate receptors most efficiently mediate the transition to the adaptive cellular immune response.

Cellular Therapy Team

CONFIDENTIAL

19

Mesenchymal Stem Cells Could Hold the Key to the Future of Ground Breaking Research

There are many areas of preclinical research4,5,6,7,8,9

Sports Injuries

Lung Disease

Stroke

Liver Repair

Rheumatoid Arthritis

Parkinson’s Disease

Type 1 Diabetes

Burn Victims

Extensive Pipeline of Future Stem Cell Applications

Osteoarthritis

More Diseases in Research with Stem Cells

CONFIDENTIAL

20

• Ataxia telangiectasia • Chronic granulomatous

disease • DiGeorge syndrome • IKK gamma deficiency • Immune dysregulation

polyendocrineopathy • X-linked Mucolipidosis,

Type II • Myelokathexis X-linked

immunodeficiency • Severe combined

immunodeficiency • Adenosine deaminase

deficiency • Wiskott-Aldrich

syndrome • X-linked

agammaglobulinemia • X-linked

lymphoproliferative disease

• Omenn's syndrome • Reticular dysplasia • Thymic dysplasia • Leukocyte adhesion

deficiency

• Sickle-cell anemia (hemoglobin SS)

• HbSC disease • Sickle βo Thalassemia • α-thalassemia major

(hydrops fetalis) • β-thalassemia major • β-thalassemia intermedia • E-βo thalassemia • E-β+ thalassemia• Osteopetrosis • Langerhans cell

histiocytosis • Hemophagocytic

lymphohistiocytosis

• Acute lymphoblastic leukemia

• Acute myeloid leukemia • Burkitt's lymphoma • Chronic myeloid leukemia • Juvenile myelomonocytic

leukemia• Non-Hodgkin's lymphoma • Hodgkin's lymphoma • Lymphomatoid

granulomatosis • Myelodysplastic syndrome • Chronic myelomonocytic

leukemia

Blood DisordersImmunodeficiences Metabolic Disorders

Cancers

Other• Osteopetrosis • Langerhans cell

histiocytosis • Hemophagocytic

lymphohistiocytosis

• Amegakaryocytic thrombocytopenia

• Autoimmune neutropenia (severe)

• Congenital dyserythropoietic anemia

• Cyclic neutropenia • Diamond-Blackfan

anemia • Evan's syndrome • Fanconi anemia • Glanzmann's disease • Juvenile dermatomyositis • Kostmann's syndrome • Red cell aplasia • Shwachman syndrome • Severe aplastic anemia • Congenital sideroblastic

anemia • Thrombocytopenia with

absent radius• (TAR syndrome) • Dyskeratosis congenita

• Adrenoleukodystrophy • Gaucher's disease • (infantile) • Metachromatic

leukodystrophy • Krabbe disease • Gunther disease • Hermansky-Pudlak

syndrome • Hurler syndrome • Hurler-Scheie syndrome • Hunter syndrome • Sanfilippo syndrome • Maroteaux-Lamy

syndrome • Mucolipidosis Type II, III • Alpha mannosidosis • Niemann Pick Syndrome,

type A and B • Sandhoff Syndrome • Tay-Sachs Disease • Batten disease• Lesch-Nyhan disease

Bone Marrow Failure Syndromes

There are Nearly 80 Diseases Treated Today

CONFIDENTIAL

And Many More in Research

21

1.Moise K Jr. Umbilical Cord Stem Cells, Obstetrics Gynecology, 2005; 106(6):1393-1407 2.Nietfield JJ, Pasquini MC, Logan BR, Verter, Horowitz MM. Lifetime Probabilities of a Hematopietic Stem Cell Transplantation in the US, Biology Blood and Marrow Transplant, 2008; 14:316-322. 3. Based on a 6/6 HLA match. 4. Stroke: Ding DC, Shyu WC, Chiang MF et al. Enhancement of Neuroplasticity through Upregulation of B1-integrin in Human Umbilical Cord Derived Stromal Stem Cell Implanted Stroke Model, Neurobiology Dis. 2007; 27(3):339-353. E-publication 2007 June 18. 5. Parkinson’s Disease: Fu YS, Cheng YC, Lin MY, et al. Conversion of Human Umbilical Cord Mesenchymal Stem Cells in Wharton’s Jelly To Dopaminergic Neurons in Vitro: Potential Therapeutic Application For Parkinson’s Disease, Stem Cells. 2006; 24(1):115-124. E-publication 2005 August. 6.Rheumatoid Arthritis: Liu Y Mu R Wang S et al. Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis, Arthritis Res Ther. 2010; 12(6):R210 7. Sports Injuries (cartilage): Wang L. Tran 1, Seshareddy K et al. A Comparison of Human Bone Marrow-Derived Mesenchymal Stem Cells and Human Umbilical Cord Derived Mesenchymal Stromal Cells for Cartilage Tissue Engineering, Tissue Eng. 2009; 15(8)(pt A): 2259-2266. 8.Type 1 Diabetes: Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes. Stem Cell Rev. October 23, 2010 E-publication. 9. Lung Cancer: Maurya DK, Doi C, Kawabata A, et al. Therapy With Un-engineered Naïve Rat Umbilical Cord Blood Matrix Stem Cells Markedly Inhibits Growth of Murine Lung Adenocarcinoma, BMC Cancer, 2010;10-590. 10. Data on file as of February 2014. 11. Accreditations current as of February 2014. 12.Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Human and Health Services, Guidance for the Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoetic Reconstitution for Specified Indications, October 2009. 13. Data on file for CariCord and numbers from company websites ViaCord (268) and CBR (262) as of February 2014. 14. Discount applies when cord blood and cord tissue banking are chosen with a prepaid storage plan. Prices effective as of February 2014General Disclaimer: Most of the diseases currently treated with cord blood stem cells are genetic diseases. Banking cord blood does not guarantee that your physicians will choose it as first line course of treatment over a sibling donor or autologous donor depending on the diseases being treated and other factors in consideration of a transplant. Only a treating physician can determine when it should be used on a case by case basis. Cord tissue research is pre-clinical and may have potential in the future but is not used in treatments in humans currently.CONFIDENTIAL